公开(公告)号：EP3827822B1

公开(公告)日：2024-11-06

申请号：EP18927746.0

申请日：2018-08-02

发明人： XU, Yingting

IPC分类号： A61K9/00 ,  A61K9/08 ,  A61K9/19 ,  A61K47/02 ,  A61K47/10 ,  A61K47/12 ,  A61K47/32 ,  A61K47/40 ,  A61P35/00 ,  A61K31/337

公开(公告)号：EP4442249A1

公开(公告)日：2024-10-09

申请号：EP23167083.7

申请日：2023-04-06

申请人： B. Braun Melsungen AG

发明人： Janas, Christine ,  Porredon Guarch, Constanca ,  Ziller, Antje ,  Bauer, Marius

IPC分类号： A61K9/00 ,  A61K31/5517 ,  A61K47/10 ,  A61K47/32 ,  A61K47/38 ,  A61K47/40 ,  A61P25/08 ,  A61P25/20 ,  A61P25/22

CPC分类号： A61K31/5517 ,  A61K9/0056 ,  A61K47/40 ,  A61K47/38 ,  A61K47/32 ,  A61K47/10 ,  A61P25/08 ,  A61K9/006

摘要： The present invention relates to a unit dosage composition comprising midazolam or a pharmaceutically acceptable salt thereof, a cyclodextrin, and at least one matrix material, as well as to the use of said unit dosage composition in medicine and therapy, in particular in the treatment of febrile seizure, epileptic seizure, such as status epilepticus, fear, such as preoperative anxiolysis to reduce fear, and/or agitation, such as agitation prior to surgery.

公开(公告)号：EP3630102B1

公开(公告)日：2024-08-14

申请号：EP18805411.8

申请日：2018-05-24

IPC分类号： A61K31/42 ,  A61K31/4545 ,  A61K31/497 ,  A61K31/554 ,  A61P25/24 ,  A61K31/405 ,  A61K9/00 ,  A61K31/135 ,  A61K31/165 ,  A61K31/4152 ,  A61K31/4525 ,  A61K31/55 ,  A61K45/06 ,  A61K47/40 ,  A61P25/00 ,  A61P25/22

CPC分类号： A61K31/4525 ,  A61K31/554 ,  A61K47/40 ,  A61P25/00 ,  A61K9/0019 ,  A61K31/135 ,  A61K31/4152 ,  A61K31/55 ,  A61K45/06 ,  A61P25/22 ,  A61P25/24 ,  A61K31/165

公开(公告)号：EP4389131A1

公开(公告)日：2024-06-26

申请号：EP22857847.2

申请日：2022-08-17

申请人： Guangzhou Ocusun Ophthalmic Biotechnology Co., Ltd. ,  Ocusun Ophthalmic Pharmaceutical (Guangzhou) Co., Ltd.

发明人： WANG, Yandong ,  SU, Yingxue ,  CAO, Chen ,  ZHOU, Sheng'an ,  XUE, Yaping ,  WU, Meirong ,  YU, Chuiliang

IPC分类号： A61K31/575 ,  A61K47/38 ,  A61K47/40 ,  A61K47/26 ,  A61K47/34 ,  A61K47/10 ,  A61K9/08 ,  A61K9/107 ,  A61K9/70 ,  A61P27/12 ,  A61P27/02

CPC分类号： A61K9/70 ,  A61K47/40 ,  A61K31/575 ,  A61K9/107 ,  A61P27/12 ,  A61K47/10 ,  A61K47/34 ,  A61K47/26 ,  A61K47/38 ,  A61P27/02 ,  A61K9/08

摘要： A pharmaceutical composition, a preparation method therefor and an application thereof. The pharmaceutical composition comprises the following components : a compound represented by formula I, hydroxypropyl methyl cellulose, benzalkonium chloride, and a pH regulator. The pharmaceutical composition can be used for preparing drugs for preventing or treating cataracts. The pharmaceutical composition has excellent stability in respect of exposure to light and to high temperatures, can be stored at room temperature, is convenient for patients to use, has pH and osmotic pressure close to those in the intraocular environment, is uniform in particle size distribution, and thus can give the patients good comfort.

公开(公告)号：EP3356440B1

公开(公告)日：2024-06-05

申请号：EP16852830.5

申请日：2016-10-03

IPC分类号： A61K9/51 ,  A61K9/10 ,  A61K9/16 ,  A61K47/38 ,  A61K47/40 ,  A61K47/36 ,  C08G18/64 ,  C08G18/76 ,  C08B37/00 ,  A61K31/12 ,  A61K31/167 ,  A61K31/337 ,  A61K31/343 ,  A61K31/496 ,  A61K31/635

CPC分类号： C08B37/0009 ,  A61K9/10 ,  A61K47/38 ,  A61K47/40 ,  A61K9/1676 ,  A61K9/1682 ,  A61K9/5161 ,  A61K31/12 ,  A61K31/167 ,  A61K31/337 ,  A61K31/343 ,  A61K31/496 ,  A61K31/635 ,  A61K47/36

公开(公告)号：EP4344699A3

公开(公告)日：2024-05-22

申请号：EP23201047.0

申请日：2023-09-29

申请人： The Board of Regents of the University of Texas System

发明人： Doan, Trang ,  Croyle, Maria

IPC分类号： A61K9/00 ,  A61K38/00 ,  A61K39/00 ,  A61K47/10 ,  A61K47/18 ,  A61K47/26 ,  A61K47/32 ,  A61K47/36 ,  A61K47/40

CPC分类号： A61K38/00 ,  A61K39/00 ,  A61K9/0053 ,  A61K9/0019 ,  A61K9/0043 ,  A61K47/26 ,  A61K47/183 ,  A61K47/32 ,  A61K47/10 ,  A61K47/36 ,  A61K47/40

摘要： Aspects of the present disclosure are directed to liquid and substantially solid film compositions for storage, transport, and administration of agents, including nucleic acids, without the use of ultralow temperatures. Provided are compositions capable of long-term storage of nucleic acids at ambient temperatures. Also disclosed are injectable or oral compositions comprising nucleic acids, as well as methods for formulation and administration of such compositions.

公开(公告)号：EP4367252A2

公开(公告)日：2024-05-15

申请号：EP22838112.5

申请日：2022-07-04

申请人： Joint Stock Company "Biocad"

发明人： FEDORENKO, Lina Igorevna ,  LOMKOVA, Ekaterina Aleksandrovna ,  IAKOVLEV, Aleksandr Olegovich ,  SOZONOVA, Aleksandra Aleksandrovna ,  DVORIANKINA, Marina Konstantinovna ,  MOROZOV, Dmitry Valentinovich

IPC分类号： C12N15/86 ,  C12N7/00 ,  A61K35/76 ,  A61K9/08 ,  A61K9/19 ,  A61K47/18 ,  A61K47/26 ,  A61K47/34 ,  A61K47/40 ,  A61K47/02

CPC分类号： Y02A50/30 ,  A61K9/08 ,  A61K9/19 ,  A61K35/76 ,  A61K47/40 ,  C12N15/86 ,  C12N2750/1414320130101 ,  C12N2750/1415120130101

公开(公告)号：EP4362928A1

公开(公告)日：2024-05-08

申请号：EP22737664.7

申请日：2022-06-29

申请人： Versantis AG

发明人： LEROUX, Jean-Christophe ,  ILIEVSKI, Filip ,  EVSTAFEVA, Diana

IPC分类号： A61K31/16 ,  A61K9/00 ,  A61P43/00 ,  C07C1/00 ,  A61K9/28 ,  A61K47/40

CPC分类号： A61K31/16 ,  A61P43/00 ,  A61K9/2846 ,  A61K9/0095 ,  A61K47/40

公开(公告)号：EP3556350B1

公开(公告)日：2024-01-10

申请号：EP19176985.0

申请日：2013-02-28

发明人： Paulus, Kerstin ,  Schwab, Wilfried ,  Grunder, Dominique ,  Van Hoogevest, Peter

IPC分类号： A61K9/08 ,  A61K9/00 ,  A61K47/18 ,  A61K47/40 ,  A61K31/517 ,  A61P31/12 ,  A61P31/22 ,  C07D239/84

公开(公告)号：EP4289418A1

公开(公告)日：2023-12-13

申请号：EP22750072.5

申请日：2022-02-07

申请人： Daewoong Co., Ltd.

发明人： SEO, Jeongdeok ,  KIM, Han-Byul ,  KIM, Kyoung-Yun

IPC分类号： A61K9/19 ,  A61K47/64 ,  A61K47/42 ,  A61K47/26 ,  A61K47/40 ,  A61K38/48

摘要： The present invention relates to a botulinum toxin freeze-dried dosage form composition storable for a long time, comprising botulinum toxin, protamine sulfate, an isotonic agent and a buffer agent, and a botulinum toxin freeze-dried dosage form according to the present invention lowers the inactivation rate of botulinum toxin during freeze-drying, can maintain the stability of botulinum toxin for longer than a conventional botulinum toxin freeze-dried dosage form, forms a uniform particle size so that the effect exhibited at the site of administration is the same and can prevent the side effect in which an excessive toxin administration effect is exhibited only at some sites.